<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049213</url>
  </required_header>
  <id_info>
    <org_study_id>202106183RIND</org_study_id>
    <nct_id>NCT05049213</nct_id>
  </id_info>
  <brief_title>Effect of Local Treatment(Carrageenan Nasal Spray and PVP-I Mouthwash) in Reducing Viral Load in Patients With COVID-19</brief_title>
  <acronym>LT-COVID19</acronym>
  <official_title>Investigating the Therapeutic Role of Topical Medical Treatment in Oral and Nasal Cavities on the Patients With Positive Severe Cute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to recruit confirmed Covid-19 patients, to evaluate whether the&#xD;
      topical anti-septic can improve clinical outcome in early Severe acute respiratory syndrome&#xD;
      coronavirus 2(SARS-CoV-2) infection. During the global pandemic period, an effective and&#xD;
      highly available method once be identified, it will reduce the risk of disease transmission&#xD;
      and lower the medical burden.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oral and nasal disinfection, a simple method with the application of commonly used antiseptic&#xD;
      agents is frequently performed in the otolaryngology and dental practice. The ability to&#xD;
      deactivate viral particles with a good safety profile may be an important benefit in the&#xD;
      control of viral proliferation and shedding. Actually, multiple anti-septic agents&#xD;
      demonstrated virucidal properties against SARS-CoV-2 in several in vitro studies. Among&#xD;
      these, Povidone-Iodine (PVP-I), common usage in otolaryngology operation and topical therapy,&#xD;
      showed high virucidal properties (0.45% PVP-I, throat spray, 4-log drop in viral load) and of&#xD;
      great safety. There is also evidence that topical usage of saline can decrease the severity&#xD;
      of upper respiratory tract infection. In addition, carrageenan, a sulphated polysaccharide&#xD;
      purified from red marine algae, had shown efficacy in inhibiting multiple viruses, including&#xD;
      in vitro studies of SARS-CoV-2. Some randomized controlled trials had also shown their&#xD;
      abilities in improving patients' symptoms with a good safety profile. Multiple international&#xD;
      organizations are conducting relating randomized clinical trials to evaluate whether the&#xD;
      topical anti-septic improves clinical outcomes after early SARS-CoV-2 infection. The added&#xD;
      value of topical antiseptic agents may be beneficial in improving symptoms, reducing viral&#xD;
      load and alleviating the rate of disease progression. Due to relatively low risk,&#xD;
      well-toleration to the general population, and highly available characteristics, the&#xD;
      potential benefits of these agents deserve more attention.&#xD;
&#xD;
      The goal of this study is to investigate the changes in clinical symptoms and sequential&#xD;
      laboratory data in confirmed COVID-19 adult patients at the early disease stage. By applying&#xD;
      topical anti-septic which is frequently used in otolaryngology procedures, the investigators&#xD;
      will evaluate the impact of this intervention on the symptoms, viral load and the rate of&#xD;
      disease progression. During the global pandemic period, an effective and highly available&#xD;
      method once be identified, it will reduce the risk of disease transmission and lower the&#xD;
      medical burden.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline naso-pharyngeal viral load quantified by RT-PCR at Day 8</measure>
    <time_frame>7 days</time_frame>
    <description>the mean change of viral titers of COVID-19 between Day 1 and Day 8 by RT-PCR test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>symptoms related to COVID-19</measure>
    <time_frame>10 days</time_frame>
    <description>including cough, fatigue, shortness of breath, loss of smell, hoarseness, chest pain, abdominal pain, diarrhea, headache, sore throat, muscle pain, etc and Quality of Life using the validated SinoNasal Outcome Tool-22 (SNOT-22, total score range 0-110, higher scores represent worse symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of adverse effects of interest after anti-septic</measure>
    <time_frame>10 days</time_frame>
    <description>including nasal discomfort, sneezing, epistaxis, headache and otalgia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of days in an ICU</measure>
    <time_frame>up to 14 days</time_frame>
    <description>number of days in an ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of days Non Invasive Ventilation (NIV) was required during hospitalization</measure>
    <time_frame>up to 14 days</time_frame>
    <description>NIV usage during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rates</measure>
    <time_frame>up to 30 days</time_frame>
    <description>mortality rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospitalization</measure>
    <time_frame>up to 14 days</time_frame>
    <description>length of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>days of discharge</measure>
    <time_frame>up to 30 days</time_frame>
    <description>free from quarantine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV 2 Infection</condition>
  <arm_group>
    <arm_group_label>Topical medical treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal spray and oral gargling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carrageenan nasal spray and 1% PVP- mouthwash and gargle</intervention_name>
    <description>Day1 to Day7&#xD;
Intranasal spray 3 times/day, 2~3 spray/nostril/per time&#xD;
Oral gargling 3 times/day, 20cc/per time</description>
    <arm_group_label>Topical medical treatment</arm_group_label>
    <other_name>BETADINE™ Cold Defense Nasal Spray and Povidone Iodine Mouthwash and Gargle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age older than 20 years of age&#xD;
&#xD;
          2. admission with a confirmed positive test for SARS-CoV-2 infection by reverse&#xD;
             transcription polymerase chain reaction (RT- PCR)&#xD;
&#xD;
          3. disease onset (start of COVID-19 symptom and PCR test) for ≤ 120 hours&#xD;
&#xD;
          4. available informed consent of this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. receiving oxygen supply before randomization&#xD;
&#xD;
          2. known intolerance/allergy to the study drugs&#xD;
&#xD;
          3. pregnancy&#xD;
&#xD;
          4. sinus/oral operation within 30 days of the beginning of the study&#xD;
&#xD;
          5. using intranasal medication before randomization&#xD;
&#xD;
          6. no available informed consent&#xD;
&#xD;
          7. inability to self-care or reply to questionnaire&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Te-Huei Yeh, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital, Department of Otolaryngology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Te-Huei Yeh, MD-PhD</last_name>
    <phone>02-23123456</phone>
    <phone_ext>65223</phone_ext>
    <email>tehueiyeh@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Te-Huei Yeh, MD-PhD</last_name>
      <phone>02-23123456</phone>
      <phone_ext>65223</phone_ext>
      <email>tehueiyeh@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Wang-Huei Sheng, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-Nan Chen, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-Kang Liao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Guenezan J, Garcia M, Strasters D, Jousselin C, Lévêque N, Frasca D, Mimoz O. Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2021 Apr 1;147(4):400-401. doi: 10.1001/jamaoto.2020.5490.</citation>
    <PMID>33538761</PMID>
  </results_reference>
  <results_reference>
    <citation>Carrouel F, Valette M, Gadea E, Esparcieux A, Illes G, Langlois ME, Perrier H, Dussart C, Tramini P, Ribaud M, Bouscambert-Duchamp M, Bourgeois D. Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial. Clin Microbiol Infect. 2021 Oct;27(10):1494-1501. doi: 10.1016/j.cmi.2021.05.028. Epub 2021 May 24.</citation>
    <PMID>34044151</PMID>
  </results_reference>
  <results_reference>
    <citation>Hasan MJ, Rumi SKNF, Banu SS, Uddin AKMN, Islam MS, Arefin MK. Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: A structured summary of a study protocol for an open-label randomized clinical trial. Trials. 2021 Jan 4;22(1):2. doi: 10.1186/s13063-020-04963-2.</citation>
    <PMID>33397432</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Anti-septic</keyword>
  <keyword>Carrageenan</keyword>
  <keyword>Nasal spray</keyword>
  <keyword>Povidone-Iodine(PVP-I)</keyword>
  <keyword>Gargle</keyword>
  <keyword>Mouthwash</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no plan to share individual participant data (IPD)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

